Search
Context Therapeutics Inc
CNTXAdd to Watchlist
0.642USD
+0.033+5.49%
Market hours （ET）Quotes delayed by 15 min
58.96MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
10
analysts
Buy
Current Rating
5.375
Target Price
+870.39%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Context Therapeutics Inc
CNTX
10
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Context Therapeutics Inc's price target?
Analysts forecast that Context Therapeutics Inc's price target is USD 4.50, with the highest forecast at USD 9.00 and the lowest forecast at USD 4.00.
How have Context Therapeutics IncCNTX's recent earnings per share performed?
The market expectation was USD -0.09, while Context Therapeutics IncCNTX's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.09.
What is the analyst rating for Context Therapeutics Inc?
Based on the ratings of Context Therapeutics Inc's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.